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Abstract
Rationale Cannabis is the most commonly used illicit drug
among pregnant women. Since the endocannabinoid system
plays a crucial role in brain development, maternal
exposure to cannabis derivatives might result in long-
lasting neurobehavioral abnormalities in the exposed
offspring. It is difficult to detect these effects, and their
underlying neurobiological mechanisms, in clinical cohorts,
because of their intrinsic methodological and interpretative
issues.
Objectives The present paper reviews relevant rodent
studies examining the long-term behavioral consequences
of exposure to cannabinoid compounds during pregnancy
and/or lactation.
Results Maternal exposure to even low doses of cannabi-
noid compounds results in atypical locomotor activity,
cognitive impairments, altered emotional behavior, and
enhanced sensitivity to drugs of abuse in the adult rodent
offspring. Some of the observed behavioral abnormalities
might be related to alterations in stress hormone levels
induced by maternal cannabis exposure.
Conclusions There is increasing evidence from animal
studies showing that cannabinoid drugs are neuroteratogens
which induce enduring neurobehavioral abnormalities in
the exposed offspring. Several preclinical findings reviewed
in this paper are in line with clinical studies reporting
hyperactivity, cognitive impairments and altered emotion-
ality in humans exposed in utero to cannabis. Conversely,
genetic, environmental and social factors could also






Since the identification of the fetal alcohol syndrome (FAS)
in the 1970s (Jones and Smith 1973), there has been a
dramatic increase in the number of clinical and preclinical
reports examining the short- and long-term effects of
maternal exposure to drugs of abuse.
While maternal exposure to high doses of alcohol,
cocaine, opiates, cannabis, and tobacco results in impaired
growth and morphological abnormalities in the offspring
(El Marroun et al. 2009; Kosofsky and Hyman 2001;
Thompson et al. 2009), low to moderate drug abuse during
pregnancy and lactation has also been related to subtle,
albeit lasting, postnatal alterations in brain function and
behavior. Research into these mostly subtle associations
between maternal drug use and offspring neurobehavioral
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behavioral teratology (Coyle et al. 1976; Vorhees 1989).
Over the years, general teratological principles have
b e e nm o d i f i e da n de x t e n d e dt or e s e a r c hi nb e h a v i o r a l
teratology, resulting in two major postulates (Vorhees 1989):
(1) vulnerability of the central nervous system (CNS) to
injury extends throughout the fetal and neonatal periods and
beyond the infancy stage, including all aspects of nervous
system development (e.g., neurogenesis, neuronal differenti-
ation, arborization, synaptogenesis, functional synaptic orga-
nization, myelination, gliogenesis, glial migration, and
differentiation), and (2) the most frequent manifestation of
injury to the developing CNS does not result in nervous
system malformations, but rather in functional abnormalities
that may not be detectable at birth.
In recent years, both clinical and preclinical studies have
shown that exposure to cannabis preparations during
pregnancy and lactation can induce behavioral teratogenic
consequences (Campolongo et al. 2009b; Fried 2002; Fried
and Smith 2001; Huizink and Mulder 2006; Navarro et al.
1995; Schneider 2009; Trezza et al. 2008b); indeed, the
main psychoactive component of cannabis, Δ9-tetrahydro-
cannabinol (THC), can cross the placenta during gestation,
and be secreted in the maternal milk during lactation
(Hutchings et al. 1989; Jakubovic et al. 1977).
Studies on the long-term behavioral abnormalities
induced by maternal cannabis exposure are of special
relevance, for two main reasons. First, nowadays cannabis
preparations are among the illicit drugs most widely used
by pregnant women in Western countries (Fried and Smith
2001); for instance, the self-reported use of cannabis during
pregnancy is approximately 2.9% in the United States
(Huizink and Mulder 2006), and reaches 5% in the United
Kingdom (Fergusson et al. 2002). Second, since the
endocannabinoid system is present and already functional
in early pregnancy (Fernandez-Ruiz et al. 2000; Fride 2008;
Harkany et al. 2007), the active ingredients of cannabis and
their metabolites could directly affect the brain by altering
endocannabinoid signaling and related neurotransmitter and
neuroendocrine systems.
A common problem in neurobehavioral teratology is that
the identification of subtle neurodevelopmental phenotypes
after exposure to drugs of abuse during pregnancy and
lactation is often elusive (Kosofsky and Hyman 2001;
Thompson et al. 2009). The effects of drugs that alter brain
development without a physical phenotype or an easily
identified neurodevelopmental behavioral phenotype such
as seizures or retardation may go undetected and under-
reported, despite significant impact on brain development
and behavior (Kosofsky and Hyman 2001). Furthermore,
clinical studies face the extreme complexities of interacting
genetic, intrauterine, and postnatal environmental factors
that contribute to the drug-induced phenotype. Thus, in
order to provide a deeper understanding of the impact of
maternal exposure to drugs of abuse on infant and child on
later development, and to adopt effective public health
strategies, it is critical to stimulate a dialogue between
clinical and preclinical investigators. While clinical studies
allow to detect basic behavior and some aspects of
functional neural activity in humans exposed to drugs of
abuse during development, they do not provide information
about the specific neuroanatomical, molecular, and cellular
consequences that underlie the observed behavioral changes
(Thompson et al. 2009). Furthermore, animal studies are
essential in controlling for prenatal and postnatal confounding
factors and for examining the independent contribution of a
certain drug to adverse neurodevelopmental consequences
(Fried 2002).
Here, we will summarize and discuss rodent studies
examining the long-term behavioral consequences induced
by exposure to cannabinoid compounds during pregnancy
and/orlactation.First,wewillfocus on the impactofmaternal
exposure to cannabinoids on motor behavior, cognitive
performance and emotionality in the rat adult offspring. Then,
we will examine the role played by maternal cannabinoid
exposureinthesusceptibilitytodiscriminativeandreinforcing
effects of drugs of abuse later in life. Last, we will provide
experimental evidence showing that maternal cannabis expo-
sure induces long-lasting changes in stress hormones which,
in turn, might underlie some of the behavioral changes
observed in the exposed offspring. We will consider only
studies that used doses of cannabinoid compounds devoid of
overtsignsoftoxicityand/orgrossmalformations,andthatare
equivalent to moderate cannabis consumption in humans. For
a review of morphological abnormalities and overt signs of
toxicity induced by maternal exposure to high doses of
cannabinoid compounds, see Abel (1980), El Marroun et al.
(2009), Fergusson et al. (2002), Linn et al. (1983).
The endocannabinoid system and the developing brain
Exhaustive research carried out during the past two decades
has demonstrated the existence of the endocannabinoid
system in the CNS and also in the periphery, which consists
of G-protein-coupled receptors (CB1 and CB2 receptors),
endogenous ligands (called endocannabinoids), and pro-
teins involved in endocannabinoid synthesis and inactiva-
tion (Di Marzo et al. 2005; Di Marzo and Petrocellis 2006;
Piomelli 2003). This recently identified system, which is
the target of psychoactive cannabis preparations, is thought
to have modulatory actions in several neurobiological
processes, as has been proposed from the anatomical
distribution of cannabinoid receptors in the brain and from
the well-known pharmacological effects of cannabinoid-
related compounds (Pacher et al. 2006; Pertwee 2008).
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during early stages of development, both in laboratory
animals and humans, and plays a relevant role in brain
organization during pre- and postnatal life (Fernandez-Ruiz
et al. 2000; Fride 2004; 2008; Harkany et al. 2007; Romero
et al. 1997). Several studies have described the presence of
the CB1 cannabinoid receptor (Rodriguez de Fonseca et al.
1993) and its endogenous ligands, anandamide and 2-AG,
in the developing brain (Berrendero et al. 1999; Harkany et
al. 2007; Mato et al. 2003). CB1 cannabinoid receptors
appear to be already functional around gestational days 11–
14 in rats (Berrendero et al. 1998), and by week 19 of
gestation in humans (Mato et al. 2003), since at these stages
they are already coupled to signal transduction mechanisms
that involve GTP-binding proteins. In both rats and
humans, the levels of CB1 receptors at fetal ages are
substantially higher than those seen in the adult brain
(Berrendero et al. 1999; Mato et al. 2003). This atypical
distribution of CB1 receptors has been interpreted, for both
species, as indicating a specific role for the endocannabi-
noid system in several developmental events, such as
metabolic support, cell proliferation and migration, axonal
elongation and later, synaptogenesis and myelogenesis
(Fernandez-Ruiz et al. 2000) .T h ep r e s e n c eo fC B 1
receptors during brain development has also been associated
with neuroprotective effects in the maturation of the CNS and
its functions (Fernandez-Ruiz et al. 2000;F r i d e2004).
Furthermore, there is a large body of evidence that
suggests that exposure to cannabinoids during critical
prenatal and early postnatal periods of brain maturation
can affect the development of several neurotransmitter
systems. In particular, several studies have demonstrated
effects of cannabinoids on the maturation of catecholaminer-
gic (Fernandez-Ruiz et al. 2000;G a r c i a - G i le ta l .1997;
Hernandez et al. 2000), serotonergic (Molina-Holgado et al.
1997;M o l i n a - H o l g a d oe ta l .1996), GABAergic (Garcia-Gil
et al. 1999), glutamatergic (Suarez et al. 2004), and
opioidergic systems (Kumar et al. 1990;V e l ae ta l .1998;
Fernandez-Ruiz et al. 2004). All this supports the idea that
endocannabinoids have a critical role in brain development,
and that targeting the endocannabinoid system by maternal
exposure to cannabinoid drugs can lead to enduring
developmental changes in the exposed offspring.
Long-term behavioral consequences of maternal
cannabis exposure
Effects on locomotor activity
The effects of developmental exposure to cannabinoids on
locomotor activity later in life are controversial. An
increased motor activity in the lactating offspring of
mothers receiving THC (10 mg/kg, subcutaneously) during
gestational days 6–12 has been reported; these effects,
however, disappeared by postnatal day 21 (Borgen et al.
1973). More recent studies are in agreement with this
previous report, demonstrating how rats, exposed to
cannabinoids during pregnancy and/or lactation, were
characterized by motor hyperactivity at infancy and
adolescence, but not at adulthood (Mereu et al. 2003;
Navarro et al. 1995). Together, these studies suggest that
maternal exposure to cannabinoid drugs might particularly
affect the ontogeny of motor behaviors, and are in line with
human data showing that children prenatally exposed to
cannabis are hyperactive and impulsive (Fried and Smith
2001; Goldschmidt et al. 2004). However, other studies
found lower activity in lactating rats perinatally exposed to
cannabinoids (Fried 1976) or no effects at all (Brake et al.
1987; Trezza et al. 2008a; Vardaris et al. 1976). Similarly,
in adult rats, maternal exposure to cannabinoid compounds
has been shown to result in either decreased activity in both
males and females (Fride and Mechoulam 1996), increased
activity in females only, or no effects (Brake et al. 1987;
Trezza et al. 2008a). The different protocols used (i.e.,
timing of exposure, route of administration, compound
used, age of testing, etc.) might account for the different
findings of these studies, and make it difficult to draw final
conclusions about the long-term effects of maternal
cannabis exposure on the locomotor activity of the
offspring. Despite the conflicting data obtained in these
studies, it is important to note that maternal administration
of low doses of cannabinoids seemed to be more effective
in inducing temporary changes in locomotor activity in the
lactating and young offspring, rather than in adult animals.
Effects on cognitive functions
Clinical studies have shown that cannabis use during
pregnancy induces selective, deleterious effects on execu-
tive functions in the offspring both at childhood and
adolescence (Day et al. 1994; Fried 2002; Fried and Smith
2001; Fried and Watkinson 2000; Fried et al. 1998).
Executive functions comprise capacities such as cognitive
flexibility, sustained and focused attention, and working
memory. The deficits in executive functions induced by
prenatal cannabis exposure seem to be long lasting, since
18–22-year-old young adults exposed to cannabis in utero
also showed altered neuronal functioning during visuospa-
tial working memory processing (Smith et al. 2006).
However, clinical data on the potential changes induced
by cannabis exposure in the long-term expression of
cognitive functions later in life are not available yet.
Furthermore, despite the consistency in these clinical
findings, it cannot be excluded that genetic and environ-
mental variables also contribute to the relationship between
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the offspring. Due to these observations, the relationship
between antenatal exposure to cannabinoid drugs and long-
term cognitive outcomes in the rodent offspring has
received a great deal of attention. Prenatal exposure to a
moderate dose of the synthetic CB1 cannabinoid receptor
agonist WIN55,212-2 induced a disruption of memory
retention in 40- and 80-day-old rat offspring tested in the
inhibitory avoidance task (Mereu et al. 2003). This
cognitive impairment was not due to alterations of non-
associative nature, since the approach latency measured
during the acquisition trials of the learning task was
unaffected. The memory impairment was associated with
alterations in both hippocampal long-term potentiation and
glutamate release. The decrease in hippocampal glutamate
overflow was suggested to be the cause of long-term
potentiation disruption, which could underlie, in turn, the
long-lasting impairment of cognitive functions caused by
the gestational exposure to the cannabinoid receptor agonist
(Mereu et al. 2003). To further support the hypothesis that
changes in glutamatergic neurotransmission might be
responsible of the cognitive impairment observed in
WIN55,212-2-exposed adult offspring, in vivo microdial-
ysis experiments showed that gestational exposure to this
cannabinoid receptor agonist induces a consistent reduction
of basal and K
+-evoked glutamate outflow in the prefrontal
cortex of the adult offspring (Antonelli et al. 2004). As for
the clinical relevance of these preclinical studies, it is
important to estimate, by extrapolation, whether the dose of
the synthetic cannabinoid agonist compares with that of
THC absorbed by cannabis users. Previous studies have
estimated that a dose of 5 mg/kg of THC in rats
corresponds to a moderate exposure to the drug in humans,
correcting for the differences in route of administration and
body weight surface area (Garcia-Gil et al. 1997; Garcia-Gil
et al. 1999). WIN 55,212-2 has been found to be three to
ten times more potent than THC, depending on the adminis-
tration route and the endpoints considered (Compton et al.
1992;F r e n c he ta l .1997; Hampson et al. 2000). Based on
these considerations, the dose of WIN55,212-2 used in the
studies described above (0.5 mg/kg, subcutaneously) might
correspond to a moderate, or even to a low, exposure to
cannabis in humans (Mereu et al. 2003). Furthermore, in line
with these earlier studies, we have recently demonstrated
that the active ingredient of cannabis THC, administered
during the perinatal period at a dose (5 mg/kg, per os,
from gestational day 15 to postnatal day 9) that is not
associated with gross malformations and/or overt signs of
toxicity, induced cognitive impairments in the adult
offspring (Campolongo et al. 2007). Perinatal exposure
to THC not only induced a long-term memory impairment
in the adult offspring, as revealed by the inhibitory
avoidance test, but also caused a disruption in short-term
olfactory memory, as assessed in the social discrimination
test (Campolongo et al. 2007).
Interestingly, the cognitive impairments observed in
THC-exposed adult offspring were associated with long-
lasting alterations in the cortical expression of genes related
to glutamatergic neurotransmission, together with a decrease
in the cortical extracellular levels of this neurotransmitter
(Campolongo et al. 2007). Taken together, these preclinical
studies show that maternal cannabis exposure alters cogni-
tive performances in the adult offspring, and strongly suggest
that changes in glutamatergic neurotransmission might be
responsible for these effects.
Effects on emotionality
Several preclinical and clinical findings support the
hypothesis of an important role of the endocannabinoid
system in the modulation of emotional states (Gaetani et al.
2009; Millan 2003; Moreira and Lutz 2008; Viveros et al.
2005; Witkin et al. 2005). First, endocannabinoids are
produced throughout the brain and CB1 cannabinoid
receptors are particularly expressed in brain areas involved
in the modulation of anxious states, such as the cortex,
hippocampus, lateral septum, nucleus accumbens, amygdala,
and PAG (Ameri 1999; Davies et al. 2002; Hermann et al.
2002; Katona et al. 2001; Schlicker and Kathmann 2001;
Tsou et al. 1998). Second, cannabinoids modulate the release
of several neurotransmitters implicated in the control of
emotionality, such as serotonin, dopamine (Hermann et al.
2002; Katona et al. 2001; Schlicker and Kathmann 2001;
Tsou et al. 1998) and the anxiogenic neuropeptides, CCK
and CRF (Ameri 1999; Rodriguez de Fonseca et al. 1997).
Third, several studies in cannabis users have shown that
exposure to hashish and marijuana in humans produces a
wide range of subjective emotional effects (Tournier et al.
2003; Wachtel et al. 2002). This may reflect the complex
pattern of influence of cannabis on neurotransmitters known
to differentially modulate anxiety states. Therefore, it is
reasonable to hypothesize that maternal cannabis exposure
might induce long-term changes in the emotional reactivity
of the offspring. To support this possibility, clinical studies
have shown that prenatal exposure to cannabis in the first
and third trimesters predicts significantly levels of self-report
anxiety and depressive symptoms in 10-year-old children
(Goldschmidt et al. 2004;G r a ye ta l .2005). However,
clinical data about the effects of maternal cannabis use on
the emotional reactivity of the offspring at adulthood are
still missing. Therefore, in addition to epidemiological
studies in humans, and considering the intrinsic limitations
of this kind of approach, animal models can contribute to
clarify if and how exposure to cannabis during pregnancy
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offspring.
We demonstratedthatperinatalexposuretoTHC(5mg/kg,
per os, from gestational day 15 to postnatal day 9) induced
long-lasting changes in the emotional reactivity of the
offspring (Trezza et al. 2008a). Indeed, compared to
vehicle-exposed offspring, THC-exposed rats emitted more
ultrasounds when removed from the nest at postnatal day 12,
and spent less time in active social interaction and social play
at adolescence (Trezza et al. 2008a). The altered emotional
reactivity found in both infant and adolescent offspring
perinatally exposed to THC was long lasting, as perinatal
THC treatment affected behavior of adult rats in the elevated
plus-maze test (Trezza et al. 2008a). Adult rats perinatally
treated with THC did indeed spend more time in the closed
arms of the maze, exhibited a significantly lower number of
head dips and a higher number of stretched-attend postures
than vehicle-exposed rats. The number of total entries,
however, was not affected by the perinatal treatment, thus
suggesting that the locomotor activity of the offspring was
not compromised by THC exposure (Trezza et al. 2008a). In
line with this finding, a decreased level of social interaction,
indicative of an increased emotionality, has been found in the
rat offspring exposed to the synthetic cannabinoid receptor
agonist CP55,940 from postnatal day 4 to postnatal day 25
(O’Shea et al. 2006). On the other hand, Newsom and Kelly
(2008) reported that exposure to THC during early postnatal
life (2 mg/kg, subcutaneously, from gestational day 1 to
postnatal day 10) increases the level of social interaction,
which could be interpreted as a decrease in emotional
reactivity.
Due to the controversies existing among the preclinical
studies and to the scarce availability of human data, further
studies are needed to clarify the effects induced by maternal
cannabinoid exposure on the emotionality of the offspring.
One possible explanation for the contrasting data may be
related to the different timing of exposure. It is well known
how different time windows of exposure to a psychotropic
agent can induce even opposite neurofunctional effects
(Costa et al. 2004). Moreover, differences in cannabinoid
agonist used, tested doses and treatment schedules could also
account for the apparent discrepancies (Schneider 2009).
In spite of the controversies, it should be taken into
account that, depending on the dose, route of administration
and environmental contexts, acute cannabinoid administra-
tion may induce both anxiolytic- or anxiogenic-like effects
in rodents (Moreira and Lutz 2008; Viveros et al. 2005). It
is crucial to consider that all studies, focusing on the
offspring emotionality, agree on the evidence that cannabi-
noid exposure during critical developmental periods may
induce, even if in an opposite way, enduring changes in the
emotional reactivity of the adult offspring.
Effects on drug sensitivity in later life
Cannabinoid and opioid neurotransmission are known to
closely interact in many physiological and pathological
functions, such as pain management, appetite regulation,
social interactions, and drug addiction (Cota et al. 2006;
Fattore et al. 2005; Maldonado and Valverde 2003; Solinas
and Goldberg 2005; Spano et al. 2009; Trezza and
Vanderschuren 2008a, b). Therefore, the possibility that
maternal cannabis consumption might affect sensitivity
towards the reinforcing properties of opioids in adulthood
has been addressed in several preclinical studies. Vela and
coworkers reported that adult female, but not male, rats
exposed to THC during pregnancy and lactation showed
increased rate of acquisition of morphine self-administration
under a fixed-ratio schedule of reinforcement at adulthood
(Vela et al. 1998). Compared to vehicle-exposed rats, THC-
exposed males exhibited a lower density of μ-opioid
receptors in the caudate-putamen area as well as in the
amygdala, whereas THC-exposed females exhibited higher
density of these receptors in the prefrontal cortex, the
hippocampus, the amygdala, the ventral tegmental area, and
the periaqueductal gray matter (Vela et al. 1998). These
results support the notion that perinatal THC exposure alters
the susceptibility to the reinforcing effects of morphine in
adult female offspring, in parallel with changes in μ-opioid
receptor binding in several brain regions. However, in a
follow-up study, the same regimen of THC administration
had no effects on both food and morphine self-administration
under a progressive-ratio schedule of reinforcement in
adulthood (Gonzalez et al. 2003). Differences in the response
requirements between fixed- and progressive-ratio schedules
of reinforcement might explain these apparently conflicting
observations. Indeed, the number of lever presses required to
obtain a drug injection is constant in fixed-ratio schedules,
while it is increased with successive injections in
progressive-ratio schedules. Thus, a fixed-ratio schedule
reveals if a drug is reinforcing or not, but the reinforcing
efficacy of this drug needs to be tested in a progressive-ratio
schedule. Therefore, we might conclude that morphine was
particularly preferred by adult females that had been
perinatally exposed to THC (Vela et al. 1998), but this
vulnerability to morphine disappeared if animals had to work
harder to get the drug (Gonzalez et al. 2003). More recently,
Spano and colleagues found that adult rats prenatally
exposed to THC did not show enhanced heroin intake under
normal conditions (Spano et al. 2007). However, enkephalin
expression in brain regions implicated in reward and stress,
such as the nucleus accumbens and amygdala, was altered
following prenatal THC exposure (Spano et al. 2007).
Furthermore, THC-exposed adult offspring showed en-
hanced heroin-seeking during mild stress and extinction
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behavioral response to stress which intensifies the motivation
for drug use in THC-exposed subjects, rather than just
altered sensitivity to the reinforcing effects of the drug.
The possibility that in utero THC exposure induces
sensitization to opiates has also been addressed by evaluating
morphine- (Rubio et al. 1998; Rubio et al. 1995)o rh e r o i n -
(Singh et al. 2006) induced place conditioning in the adult rat
offspring. In both cases, the results showed that THC-
exposed adult offspring exhibited an enhanced sensitivity to
the rewarding effects of opioid drugs.
Concerning the effects of maternal cannabis exposure on
adult sensitivity to other drugs of abuse, Economidou and
coworkers reported no effects of perinatal THC exposure
on ethanol self-administration in the adult offspring
(Economidou et al. 2007). However, the effects of maternal
cannabis exposure on adult sensitivity to drugs like
psychostimulants, hallucinogens, and also cannabinoids
are still unknown. Therefore, more studies are needed in
order to determine whether maternal cannabis use has a
direct casual influence on other illicit drug use. Further-
more, it is also important to note that preclinical studies
about the relationship between maternal cannabis exposure
and drug abuse later in life do not exclude the contribution
of other factors such as environment and social issues that
could influence the direct neurobiological effects of early
THC exposure to either enhance or attenuate the progres-
sion to adult drug abuse. Caution is therefore advised when
extending the results of these studies to human drug abuse.
Other behavioral effects
Consistent data are available about the effects of maternal
cannabis exposure on reflex reactivity to external stimuli in
the offspring. Oral administration of THC to pregnant rats
did not change the auditory startle response of the offspring
at adulthood (Hutchings et al. 1991). More recent studies
confirmed this early finding by showing that prenatal
cannabinoid exposure did not affect startle magnitude and
sensorimotor gating in the offspring tested at 40, 60, and
80 days of age (Bortolato et al. 2006). Together, these
studies suggest that prenatal exposure to cannabis deriva-
tives does not affect reflex reactivity to environmental
stimuli in the offspring.
Perinatal exposure to cannabinoid compounds increased
the frequency and the time spent by adult rats in
spontaneous and water-induced grooming behavior mea-
sured in a novel environment (Navarro et al. 1995): this
indicates that maternal cannabis exposure induces stereo-
typed behaviors that might be the consequence of an altered
response to novelty (Navarro et al. 1995).
Early studies showed that perinatal cannabinoid expo-
sure altered sexual behavior of adult male mice (Dalterio
and Bartke 1979; Dalterio et al. 1984a; b) and rats (Fried
and Charlebois 1979) that showed a longer latency to
mount a receptive female. Subsequent studies confirmed
these early findings, by showing that maternal exposure to
cannabis extracts altered the pattern of approach to sexually
receptive females in a sexual orientation test in the male rat
offspring (Navarro et al. 1996).
A complete overview of the long-term behavioral effects
of maternal cannabinoid exposure in rats is given in Table 1.
Long-term neuroendocrine effects induced by maternal
cannabis exposure
The endocannabinoid system is known to modulate the
activity of the hypothalamus–pituitary–adrenal (HPA) axis
(Cota 2008; Hill and McEwen 2009b; Rodriguez de Fonseca
et al. 1991; Weidenfeld et al. 1994). Interestingly, the effects
of endocannabinoids on the HPA axis are consistent with
their neuromodulatory action on brain neurotransmitter
systems. For instance, endocannabinoids have been found
to mediate the nongenomic glucocorticoid-induced inhibition
of glutamate release within the paraventricular nucleus of the
hypothalamus (Di et al. 2003), or to mediate glucocorticoid-
induced inhibition of spontaneous neuronal activity and
sensory responsiveness of medullary neurons (Coddington
et al. 2007). These data, together with our recent findings
showing that endocannabinoids mediate glucocorticoid-
induced enhancement of emotional memory processing in
the amygdala (Campolongo et al. 2009a) ,l e dt ot h e
hypothesis that endocannabinoids might play a crucial role
in the fast nongenomic neuronal actions of glucocorticoids
(Hill and McEwen 2009a).
Glucocorticoids, in turn, are well-known epigenetic
factors able to affect brain development (McEwen 1992),
and it has been suggested that activation of the HPA axis
might underlie the neurobehavioral changes observed after
perinatal exposure to either drugs of abuse or stress
(McEwen 1987). Therefore, it is possible that some of the
neurodevelopmental effects induced by maternal cannabis
exposure might be due to changes in the epigenetic role of
stress hormones on brain development. Data from animal
studies support this possibility. It has been reported that
adult female rats exposed to THC during pregnancy and
lactation exhibited higher levels of both corticotrophin
releasing factor (CRF-41) in the medial basal hypothalamus
and plasma corticosterone, whereas THC-exposed males
showed lower levels of both endocrine parameters (Navarro
et al. 1995; Rubio et al. 1995). In a subsequent study, the
same group showed that perinatal exposure to doses of the
synthetic cannabinoid agonist HU-210 equipotent to human
cannabis consumption resulted in a dose-dependent de-
crease in plasma corticosterone levels in the adult male





THC 10 mg/kg (s.c.) GD 6-GD 12 Increased motor activity, that disappeared by PND21 Borgen et al. 1973
THC 5 mg/kg (p.o.) GD 5-PND 24 Increased motor activity, most evident at preweaning
ages in both males and females, and also in
adult females
Navarro et al. 1995
THC 5 mg/kg (p.o.) GD 15-PND 9 No effects at PND 12, 35 and 80 (males) Trezza et al. 2008a
THC 2 mg/kg (p.o.) GD 3-GD22 No effects at PND 21 and 90 in both sexes Vardaris et al. 1976
THC 15–50 mg/kg (p.o.) GD 8-GD 22 No effects from PND 1 till PND 32 Brake et al. 1987
THC 3.3 mg/kg approximately (p.i.) GD 1-GD 19 Reduced motor activity at PND 7, but not at PND 14 Fried 1976
WIN55,212–2 0.5 mg/kg (s.c.) GD 5-GD 20 Hyperactivity at PND 12 and 40, but not at PND
80 (males)
Mereu et al. 2003
Cognitive functions
WIN55,212–2 0.5 mg/kg (s.c.) GD 5-GD 20 Disruption of memory retention in the inhibitory
avoidance task at PND 40 and 80 (males)
Mereu et al. 2003
THC 5 mg/kg (p.o.) GD 15-PND 9 Long-term memory impairment in the inhibitory
avoidance test and impaired olfactory short-term
memory in the social discrimination task
(PND 80, males)
Campolongo et al. 2007
Emotionality
THC 5 mg/kg (p.o.) GD 15-PND 9 Increased rate of separation-induced ultrasonic
vocalizations at PND 12; reduced social interaction
and play behavior at PND 35; increased anxiety-
related behavior in the elevated plus-maze test at
PND 80 (males)
Trezza et al. 2008a
CP55,940 (increasing doses: 0.15, 0.20,
0.30 mg/kg for 7 days at each dose, s.c.)
PND 4-PND 25 Reduced social interaction at PND 60 (males) O’Shea et al. 2006
THC 2 mg/kg (s.c.) GD 1-PND 10 Increased social interaction at PND 90 (males) Newsom and Kelly 2008
Drug sensitivity later in life
THC 5 mg/kg (p.o.) GD 5-PND 24 Increased rate of acquisition of morphine
self-administration under a fixed-ratio schedule in
adult females (no effects in males)
Vela et al. 1998
THC 5 mg/kg (p.o.) GD 5-PND 24 No effect on food or morphine self-administration
in a progressive-ratio schedule in both adult males
and females
Gonzalez et al. 2003
THC 0.15 mg/kg (i.v.) GD 5-PND 2 No differences in heroine self-administration under
normal conditions; however, increased heroin-
seeking
during mild stress and extinction (PND 62, males)
Spano et al. 2007
THC 1–5 mg/kg (p.o.) GD 5-PND 24 Enhanced sensitivity towards the rewarding effects of
morphine in a conditioned place preference paradigm
both in adult males and females
Rubio et al. 1998
THC 5 mg/kg (p.o.) GD 5-PND 24 Enhanced sensitivity towards the rewarding effects of
morphine in a conditioned place preference paradigm
both in adult males and females
Rubio et al. 1995
THC 5 mg/kg (p.o.) GD 15-PND 9 No effects on ethanol self-administration in adult males Economidou et al. 2007
Other behavioral effects
THC 15–30 mg/kg (p.o.) GD 2-GD 22 No effects on auditory startle at PND 57–60 in both
males and females
Hutchings et al. 1991
WIN55,212-2 0.5–1 mg/kg (s.c.) GD 5-GD 20 No effects on startle magnitude and sensorimotor
gating at PND 40, 60 and 80 (males)
Bortolato et al. 2006
THC 5 mg/kg (p.o.) GD 5-PND 24 Increase in the frequency and time spent grooming in
both adult males and females
Navarro et al. 1995
Hashish extract 20 mg/kg (p.o.) GD 5-PND 24 Altered pattern of approach of adult males
toward sexually receptive females
Navarro et al. 1996
GD gestational day, PND postnatal day, p.o. per os, s.c. subcutaneously, i.v. intravenously, p.i. per inhalation
Psychopharmacology (2011) 214:5–15 11offspring, and in clear alterations in the responsiveness of
the HPA axis to an acute stimulatory challenge with HU-
210 (del Arco et al. 2000). The authors suggest that these
endocrine alterations might reflect compensatory mecha-
nisms for the presence of higher levels of corticosterone
during fetal development following a HU-210-induced
increase in corticosterone in maternal blood (Rodriguez de
Fonseca et al. 1995; Ward and Weisz 1984). Interestingly,
offspring perinatally exposed to high levels of the synthetic
cannabinoid agonist showed a decreased responsiveness of
the HPA axis to stressors at adult ages, whereas offspring
perinatally exposed to low levels of the same cannabinoid
compound showed a sensitization of the HPA axis (del
Arco et al. 2000). Thesedatapointoutthatmaternalexposure
to even low doses of cannabinoid compounds induces long-
lasting alterations in the functionality of the HPA axis that, in
turn, might result in an impairment in the behavioral and
neuroendocrine response to stress in the adult offspring. To
support this interpretation, it has been shown that neonatal
administration of THC alters the neurochemical response to
stress in adult rats (Mokler et al. 1987). Further research,
however, is needed to establish the precise role of stress
hormones in the neurobehavioral consequences induced by
maternal cannabis exposure.
Conclusions
The effects of maternal drug exposure on brain develop-
ment and behavior later in life are complex, and are
modulated by several factors like timing, dose, and route of
drug exposure. Investigating these effects in human studies
is difficult, due to frequent simultaneous exposure to
multiple drugs, difficulties in documenting use patterns,
influence of social and genetic factors, and practical
problems in conducting long-term prospective longitudinal
studies. Therefore, preclinical studies provide a unique
opportunity to identify the long-lasting behavioral abnormal-
ities induced by maternal drug exposure, and the specific
neuroanatomical, molecular, and cellular changes that under-
lie these behavioral effects (Thompson et al. 2009).
The preclinical studies reviewed in this article outlined
that cannabinoid drugs are neuroteratogens able to induce
long-lasting behavioral abnormalities in the exposed off-
spring. In particular, administration of even low doses of
cannabinoid compounds during development results in
atypical development of locomotor activity, cognitive
impairments, altered emotional behavior and enhanced drug
sensitivity later in life. Although most longitudinal pro-
spective studies (Fried 2002; Fried and Smith 2001;
Goldschmidt et al. 2004; Gray et al. 2005; Smith et al.
2006) about the long-term effects of maternal cannabis
exposure in humans are still in progress, some of the
preclinical findings reviewed in this article are in line with
clinical studies reporting hyperactivity, cognitive impair-
ments, and altered emotionality in humans exposed to
cannabis during pregnancy and/or lactation (Fried and
Smith 2001; Fried et al. 1992; Goldschmidt et al. 2000;
2004; Gray et al. 2005; Smith et al. 2006). This parallelism
further support the utility of animal studies in getting
information about the long-term neurobehavioral outcomes
of maternal cannabis use that is relevant to the human
exposure. Conversely, although animal models allow to
control for several confounding factors associated with
human studies, they do not take into account environmental
and social factors that could influence the long-term
neurobehavioral effects of maternal cannabis exposure.
This issue is particularly important when assessing the
effects of early cannabis exposure on drug sensitivity later
in life. Therefore, it is clear that only a dialogue between
clinical and preclinical investigators will allow to determine
the precise risk of maternal cannabis use, the neurobiolog-
ical mechanisms underlying the altered behavioral pheno-
type observed in cannabis-exposed subjects, and the
interaction between drug exposure and other factors that
influence fetal brain development, like maternal stress,
social, genetic, and environmental factors.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are
credited.
References
Abel EL (1980) Prenatal exposure to cannabis: a critical review of
effects on growth, development, and behavior. Behav Neural Biol
29:137–156
Ameri A (1999) The effects of cannabinoids on the brain. Prog
Neurobiol 58:315–348
Antonelli T, Tanganelli S, Tomasini MC, Finetti S, Trabace L, Steardo
L, Sabino V, Carratu MR, Cuomo V, Ferraro L (2004) Long-term
effects on cortical glutamate release induced by prenatal exposure
to the cannabinoid receptor agonist (R)-(+)-[2, 3-dihydro-5-methyl-
3-(4-morpholinyl-methyl)pyrrolo[1, 2, 3-de]-1, 4-benzoxazin-6-yl]-
1-naphthalenylmethanone: an in vivo microdialysis study in the
awake rat. Neuroscience 124:367–375
Berrendero F, Garcia-Gil L, Hernandez ML, Romero J, Cebeira M, de
Miguel R, Ramos JA, Fernandez-Ruiz JJ (1998) Localization of
mRNA expression and activation of signal transduction mecha-
nisms for cannabinoid receptor in rat brain during fetal
development. Development 125:3179–3188
Berrendero F, Sepe N, Ramos JA, Di Marzo V, Fernandez-Ruiz JJ
(1999) Analysis of cannabinoid receptor binding and mRNA
expression and endogenous cannabinoid contents in the devel-
oping rat brain during late gestation and early postnatal period.
Synapse 33:181–191
Borgen LA, Lott GC, Davis WM (1973) Cannabis-induced hypothermia:
a dose-effect comparison of crude marihuana extract and synthetic
12 Psychopharmacology (2011) 214:5–159-tetrahydrocannabinol in male and female rats. Res Commun
Chem Pathol Pharmacol 5:621–626
Bortolato M, Frau R, Orru M, Casti A, Aru GN, Fa M, Manunta M,
Usai A, Mereu G, Gessa GL (2006) Prenatal exposure to a
cannabinoid receptor agonist does not affect sensorimotor gating
in rats. Eur J Pharmacol 531:166–170
Brake SC, Hutchings DE, Morgan B, Lasalle E, Shi T (1987) Delta-9-
tetrahydrocannabinol during pregnancy in the rat: II. Effects on
ontogeny of locomotor activity and nipple attachment in the
offspring. Neurotoxicol Teratol 9:45–49
CampolongoP,TrezzaV,Cassano T,GaetaniS,MorgeseMG,UbaldiM,
Soverchia L, Antonelli T, Ferraro L, Massi M, Ciccocioppo R,
CuomoV(2007)Perinatalexposuretodelta-9-tetrahydrocannabinol
causes enduring cognitive deficits associated with alteration of
cortical gene expression and neurotransmission in rats. Addict Biol
12:485–495
Campolongo P, Roozendaal B, Trezza V, Hauer D, Schelling G,
McGaugh JL, Cuomo V (2009a) Endocannabinoids in the rat
basolateral amygdala enhance memory consolidation and enable
glucocorticoid modulation of memory. Proc Natl Acad Sci USA
106:4888–4893
Campolongo P, Trezza V, Palmery M, Trabace L, Cuomo V (2009b)
Developmental exposure to cannabinoids causes subtle and endur-
ing neurofunctional alterations. Int Rev Neurobiol 85:117–133
Coddington E, Lewis C, Rose JD, Moore FL (2007) Endocannabi-
noids mediate the effects of acute stress and corticosterone on sex
behavior. Endocrinology 148:493–500
Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR (1992)
Aminoalkylindole analogs: cannabimimetic activity of a class of
compounds structurally distinct from delta 9-tetrahydrocannabinol.
J Pharmacol Exp Ther 263:1118–1126
Costa LG, Steardo L, Cuomo V (2004) Structural effects and
neurofunctional sequelae of developmental exposure to psycho-
therapeutic drugs: experimental and clinical aspects. Pharmacol
Rev 56:103–147
Cota D (2008) The role of the endocannabinoid system in the
regulation of hypothalamic-pituitary-adrenal axis activity. J
Neuroendocrinol 20(Suppl 1):35–38
Cota D, Tschop MH, Horvath TL, Levine AS (2006) Cannabinoids,
opioids and eating behavior: the molecular face of hedonism?
Brain Res Brain Res Rev 51:85–107
Coyle I, Wayner MJ, Singer G (1976) Behavioral teratogenesis: a
critical evaluation. Pharmacol Biochem Behav 4:191–200
Dalterio S, Bartke A (1979) Perinatal exposure to cannabinoids alters
male reproductive function in mice. Science 205:1420–1422
Dalterio S, Steger R, Mayfield D, Bartke A (1984a) Early cannabinoid
exposure influences neuroendocrine and reproductive functions
in male mice: I. Prenatal exposure. Pharmacol Biochem Behav
20:107–113
Dalterio S, Steger R, Mayfield D, Bartke A (1984b) Early cannabinoid
exposure influences neuroendocrine and reproductive functions
in mice: II. Postnatal effects. Pharmacol Biochem Behav 20:
115–123
Davies SN, Pertwee RG, Riedel G (2002) Functions of cannabinoid
receptors in the hippocampus. Neuropharmacology 42:993–1007
Day NL, Richardson GA, Goldschmidt L, Robles N, Taylor PM,
Stoffer DS, Cornelius MD, Geva D (1994) Effect of prenatal
marijuana exposure on the cognitive development of offspring at
age three. Neurotoxicol Teratol 16:169–175
del Arco I, Munoz R, Rodriguez De Fonseca F, Escudero L, Martin-
Calderon JL, Navarro M, Villanua MA (2000) Maternal exposure
to the synthetic cannabinoid HU-210: effects on the endocrine
and immune systems of the adult male offspring. Neuroimmu-
nomodulation 7:16–26
Di Marzo V, Petrocellis LD (2006) Plant, synthetic, and endogenous
cannabinoids in medicine. Annu Rev Med 57:553–574
Di Marzo V, De Petrocellis L, Bisogno T (2005) The biosynthesis, fate
and pharmacological properties of endocannabinoids. Handb Exp
Pharmacol 147–185
Di S, Malcher-Lopes R, Halmos KC, Tasker JG (2003) Nongenomic
glucocorticoid inhibition via endocannabinoid release in the
hypothalamus: a fast feedback mechanism. J Neurosci 23:
4850–4857
Economidou D, Mattioli L, Ubaldi M, Lourdusamy A, Soverchia L,
Hardiman G, Campolongo P, Cuomo V, Ciccocioppo R (2007)
Role of cannabinoidergic mechanisms in ethanol self-
administration and ethanol seeking in rat adult offspring
following perinatal exposure to Delta9-tetrahydrocannabinol.
Toxicol Appl Pharmacol 223:73–85
El Marroun H, Tiemeier H, Steegers EA, Jaddoe VW, Hofman A,
Verhulst FC, van den Brink W, Huizink AC (2009) Intrauterine
cannabis exposure affects fetal growth trajectories: the generation
R Study. J Am Acad Child Adolesc Psychiatry
Fattore L, Deiana S, Spano SM, Cossu G, Fadda P, Scherma M, Fratta
W (2005) Endocannabinoid system and opioid addiction:
behavioural aspects. Pharmacol Biochem Behav 81:343–359
Fergusson DM, Horwood LJ, Northstone K (2002) Maternal use of
cannabis and pregnancy outcome. Bjog 109:21–27
Fernandez-Ruiz J, Berrendero F, Hernandez ML, Ramos JA (2000)
The endogenous cannabinoid system and brain development.
Trends Neurosci 23:14–20
Fernandez-Ruiz J, Gomez M, Hernandez M, de Miguel R, Ramos JA
(2004) Cannabinoids and gene expression during brain develop-
ment. Neurotox Res 6:389–401
French ED, Dillon K, Wu X (1997) Cannabinoids excite dopamine
neurons in the ventral tegmentum and substantia nigra. Neuro-
Report 8:649–652
Fride E (2004) The endocannabinoid-CB(1) receptor system in pre-
and postnatal life. Eur J Pharmacol 500:289–297
Fride E (2008) Multiple roles for the endocannabinoid system during
the earliest stages of life: pre- and postnatal development. J
Neuroendocrinol 20(Suppl 1):75–81
Fride E, Mechoulam R (1996) Developmental aspects of anandamide:
ontogeny of response and prenatal exposure. Psychoneuroendoc-
rinology 21:157–172
Fried PA (1976) Short and long-term effects of pre-natal cannabis
inhalation upon rat offspring. Psychopharmacology (Berl)
50:285–291
Fried PA (2002) Conceptual issues in behavioral teratology and their
application in determining long-term sequelae of prenatal
marihuana exposure. J Child Psychol Psychiatry 43:81–102
Fried PA, Charlebois AT (1979) Cannabis administered during
pregnancy: First—and second—generation effects in rats. Physiol
Psychol 307–310
Fried PA, Smith AM (2001) A literature review of the consequences of
prenatal marihuana exposure. An emerging theme of a deficiency in
aspects of executive function. Neurotoxicol Teratol 23:1–11
Fried PA, Watkinson B (2000) Visuoperceptual functioning differs in
9- to 12-year olds prenatally exposed to cigarettes and marihua-
na. Neurotoxicol Teratol 22:11–20
Fried PA, Watkinson B, Gray R (1992) A follow-up study of attentional
behavior in 6-year-old children exposed prenatally to marihuana,
cigarettes, and alcohol. Neurotoxicol Teratol 14:299–311
Fried PA, Watkinson B, Gray R (1998) Differential effects on
cognitive functioning in 9- to 12-year olds prenatally exposed
to cigarettes and marihuana. Neurotoxicol Teratol 20:293–306
Gaetani S, Dipasquale P, Romano A, Righetti L, Cassano T, Piomelli D,
Cuomo V (2009) The endocannabinoid system as a target for novel
anxiolytic and antidepressant drugs. Int Rev Neurobiol 85:57–72
Garcia-Gil L, De Miguel R, Munoz RM, Cebeira M, Villanua MA,
Ramos JA, Fernandez-Ruiz JJ (1997) Perinatal delta(9)-tetrahy-
drocannabinol exposure alters the responsiveness of hypothalam-
Psychopharmacology (2011) 214:5–15 13ic dopaminergic neurons to dopamine-acting drugs in adult rats.
Neurotoxicol Teratol 19:477–487
Garcia-Gil L, de Miguel R, Romero J, Perez A, Ramos JA, Fernandez-
Ruiz JJ (1999) Perinatal delta9-tetrahydrocannabinol exposure
augmented the magnitude of motor inhibition caused by GABA
(B), but not GABA(A), receptor agonists in adult rats. Neuro-
toxicol Teratol 21:277–283
Goldschmidt L, Day NL, Richardson GA (2000) Effects of prenatal
marijuana exposure on child behavior problems at age 10.
Neurotoxicol Teratol 22:325–336
Goldschmidt L, Richardson GA, Cornelius MD, Day NL (2004)
Prenatal marijuana and alcohol exposure and academic achieve-
ment at age 10. Neurotoxicol Teratol 26:521–532
Gonzalez B, de Miguel R, Martin S, Perez-Rosado A, Romero J,
Garcia-Lecumberri C, Fernandez-Ruiz J, Ramos JA, Ambrosio E
(2003) Effects of perinatal exposure to delta 9-tetrahydrocannabinol
on operant morphine-reinforced behavior. Pharmacol Biochem
Behav 75:577–584
Gray KA, Day NL, Leech S, Richardson GA (2005) Prenatal
marijuana exposure: effect on child depressive symptoms at ten
years of age. Neurotoxicol Teratol 27:439–448
Hampson RE, Mu J, Deadwyler SA (2000) Cannabinoid and kappa
opioid receptors reduce potassium K current via activation of G
(s) proteins in cultured hippocampal neurons. J Neurophysiol
84:2356–2364
Harkany T, Guzman M, Galve-Roperh I, Berghuis P, Devi LA,
Mackie K (2007) The emerging functions of endocannabinoid
signaling during CNS development. Trends Pharmacol Sci
28:83–92
Hermann H, Marsicano G, Lutz B (2002) Coexpression of the
cannabinoid receptor type 1 with dopamine and serotonin
receptors in distinct neuronal subpopulations of the adult mouse
forebrain. Neuroscience 109:451–460
Hernandez M, Berrendero F, Suarez I, Garcia-Gil L, Cebeira M,
Mackie K, Ramos JA, Fernandez-Ruiz J (2000) Cannabinoid CB
(1) receptors colocalize with tyrosine hydroxylase in cultured
fetal mesencephalic neurons and their activation increases the
levels of this enzyme. Brain Res 857:56–65
Hill MN, McEwen BS (2009a) Endocannabinoids: the silent partner of
glucocorticoids in the synapse. Proc Natl Acad Sci USA
106:4579–4580
Hill MN, McEwen BS (2009b) Involvement of the endocannabinoid
system in the neurobehavioural effects of stress and glucocorti-
coids. Prog Neuropsychopharmacol Biol Psychiatry
Huizink AC, Mulder EJ (2006) Maternal smoking, drinking or cannabis
use during pregnancy and neurobehavioral and cognitive function-
ing in human offspring. Neurosci Biobehav Rev 30:24–41
Hutchings DE, Martin BR, Gamagaris Z, Miller N, Fico T (1989)
Plasma concentrations of delta-9-tetrahydrocannabinol in dams
and fetuses following acute or multiple prenatal dosing in rats.
Life Sci 44:697–701
Hutchings DE, Brake SC, Banks AN, Nero TJ, Dick LS, Zmitrovich
AC (1991) Prenatal delta-9-tetrahydrocannabinol in the rat:
effects on auditory startle in adulthood. Neurotoxicol Teratol
13:413–416
Jakubovic A, Hattori T, McGeer PL (1977) Radiactivity in suckled
rats after giving 14C-tetrahydrocannabinol to the mother. Eur J
Pharmacol 22:221–223
Jones KL, Smith DW (1973) Recognition of the fetal alcohol
syndrome in early infancy. Lancet 2:999–1001
Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N, Freund
TF (2001) Distribution of CB1 cannabinoid receptors in the
amygdala and their role in the control of GABAergic transmis-
sion. J Neurosci 21:9506–9518
Kosofsky BE, Hyman SE (2001) No time for complacency: the fetal
brain on drugs. J Comp Neurol 435:259–262
Kumar AM, Haney M, Becker T, Thompson ML, Kream RM, Miczek
K (1990) Effect of early exposure to delta-9-tetrahydrocannabinol
on the levels of opioid peptides, gonadotropin-releasing hormone
and substance P in the adult male rat brain. Brain Res 525:78–83
Linn S, Schoenbaum SC, Monson RR, Rosner R, Stubblefield PC,
Ryan KJ (1983) The association of marijuana use with outcome
of pregnancy. Am J Public Health 73:1161–1164
Maldonado R, Valverde O (2003) Participation of the opioid system in
cannabinoid-induced antinociception and emotional-like
responses. Eur Neuropsychopharmacol 13:401–410
Mato S, Del Olmo E, Pazos A (2003) Ontogenetic development of
cannabinoid receptor expression and signal transduction func-
tionality in the human brain. Eur J Neurosci 17:1747–1754
McEwen BS (1987) Steroid hormones and brain development: some
guidelines for understanding actions of pseudohormones and
other toxic agents. Environ Health Perspect 74:177–184
McEwen BS (1992) Steroid hormones: effect on brain development
and function. Horm Res 37(Suppl 3):1–10
Mereu G, Fa M, Ferraro L, Cagiano R, Antonelli T, Tattoli M,
Ghiglieri V, Tanganelli S, Gessa GL, Cuomo V (2003) Prenatal
exposure to a cannabinoid agonist produces memory deficits
linked to dysfunction in hippocampal long-term potentiation and
glutamate release. Proc Natl Acad Sci USA 100:4915–4920
Millan MJ (2003) The neurobiology and control of anxious states.
Prog Neurobiol 70:83–244
Mokler DJ, Robinson SE, Johnson JH, Hong JS, Rosecrans JA (1987)
Neonatal administration of delta-9-tetrahydrocannabinol (THC)
alters the neurochemical response to stress in the adult Fischer-
344 rat. Neurotoxicol Teratol 9:321–327
Molina-Holgado F, Amaro A, Gonzalez MI, Alvarez FJ, Leret ML
(1996) Effect of maternal delta 9-tetrahydrocannabinol on
developing serotonergic system. Eur J Pharmacol 316:39–42
Molina-Holgado F, Alvarez FJ, Gonzalez I, Antonio MT, Leret ML
(1997) Maternal exposure to delta 9-tetrahydrocannabinol (delta
9-THC) alters indolamine levels and turnover in adult male and
female rat brain regions. Brain Res Bull 43:173–178
Moreira FA, Lutz B (2008) The endocannabinoid system: emotion,
learning and addiction. Addict Biol 13:196–212
Navarro M, Rubio P, de Fonseca FR (1995) Behavioural consequen-
ces of maternal exposure to natural cannabinoids in rats.
Psychopharmacology (Berl) 122:1–14
Navarro M, de Miguel R, Rodriguez de Fonseca F, Ramos JA,
Fernandez-Ruiz JJ (1996) Perinatal cannabinoid exposure modi-
fies the sociosexual approach behavior and the mesolimbic
dopaminergic activity of adult male rats. Behav Brain Res
75:91–98
Newsom RJ, Kelly SJ (2008) Perinatal delta-9-tetrahydrocannabinol
exposure disrupts social and open field behavior in adult male
rats. Neurotoxicol Teratol 30:213–219
O’Shea M, McGregor IS, Mallet PE (2006) Repeated cannabinoid
exposure during perinatal, adolescent or early adult ages
produces similar long-lasting deficits in object recognition and
reduced social interaction in rats. J Psychopharmacol
Pacher P, Batkai S, Kunos G (2006) The endocannabinoid system as an
emerging target of pharmacotherapy. Pharmacol Rev 58:389–462
Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology
of three plant cannabinoids: delta9-tetrahydrocannabinol, canna-
bidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol
153:199–215
Piomelli D (2003) The molecular logic of endocannabinoid signalling.
Nat Rev Neurosci 4:873–884
Rodriguez de Fonseca F, Fernandez-Ruiz JJ, Murphy L, Eldridge JC,
Steger RW, BartkeA (1991) Effectsofdelta-9-tetrahydrocannabinol
exposure on adrenal medullary function: evidence of an acute effect
and development of tolerance in chronic treatments. Pharmacol
Biochem Behav 40:593–598
14 Psychopharmacology (2011) 214:5–15Rodriguez de Fonseca F, Ramos JA, Bonnin A, Fernandez-Ruiz JJ
(1993) Presence of cannabinoid binding sites in the brain from
early postnatal ages. NeuroReport 4:135–138
Rodriguez de Fonseca FR, Villanua MA, Munoz RM, San-Martin-Clark
O, Navarro M (1995) Differential effects of chronic treatment with
either dopamine D1 or D2 receptor agonists on the acute
neuroendocrine actions of the highly potent synthetic cannabinoid
HU-210 in male rats. Neuroendocrinology 61:714–721
Rodriguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss
F (1997) Activation of corticotropin-releasing factor in the
limbic system during cannabinoid withdrawal. Science 276:
2050–2054
Romero J, Garcia-Palomero E, Berrendero F, Garcia-Gil L, Hernandez
ML, Ramos JA, Fernandez-Ruiz JJ (1997) Atypical location of
cannabinoid receptors in white matter areas during rat brain
development. Synapse 26:317–323
Rubio P, Rodriguez de Fonseca F, Munoz RM, Ariznavarreta C,
Martin-Calderon JL, Navarro M (1995) Long-term behavioral
effects of perinatal exposure to delta 9-tetrahydrocannabinol
in rats: possible role of pituitary-adrenal axis. Life Sci
56:2169–2176
Rubio P, Rodriguez de Fonseca F, Martin-Calderon JL, Del Arco I,
Bartolome S, Villanua MA, Navarro M (1998) Maternal exposure
to low doses of delta9-tetrahydrocannabinol facilitates morphine-
induced place conditioning in adult male offspring. Pharmacol
Biochem Behav 61:229–238
Schlicker E, Kathmann M (2001) Modulation of transmitter release
via presynaptic cannabinoid receptors. Trends Pharmacol Sci
22:565–572
Schneider M (2009) Cannabis use in pregnancy and early life and its
consequences: animal models. Eur Arch Psychiatry Clin Neuro-
sci 259:383–393
Singh ME, McGregor IS, Mallet PE (2006) Perinatal exposure to delta
(9)-tetrahydrocannabinol alters heroin-induced place condition-
ing and fos-immunoreactivity. Neuropsychopharmacology
31:58–69
Smith AM, Fried PA, Hogan MJ, Cameron I (2006) Effects of prenatal
marijuana on visuospatial working memory: an fMRI study in
young adults. Neurotoxicol Teratol 28:286–295
Solinas M, Goldberg SR (2005) Motivational effects of cannabinoids
and opioids on food reinforcement depend on simultaneous
activation of cannabinoid and opioid systems. Neuropsychophar-
macology 30:2035–2045
Spano MS, Ellgren M, Wang X, Hurd YL (2007) Prenatal cannabis
exposure increases heroin seeking with allostatic changes in
limbic enkephalin systems in adulthood. Biol Psychiatry 61:
554–563
Spano MS, Fadda P, Fratta W, Fattore L (2009) Cannabinoid-opioid
interactions in drug discrimination and self-administration: effect
of maternal, postnatal, adolescent and adult exposure to the
drugs. Curr Drug Targets
Suarez I, Bodega G, Fernandez-Ruiz J, Ramos JA, Rubio M,
Fernandez B (2004) Down-regulation of the AMPA glutamate
receptor subunits GluR1 and GluR2/3 in the rat cerebellum
following pre- and perinatal delta9-tetrahydrocannabinol expo-
sure. Cerebellum 3:66–74
Thompson BL, Levitt P, Stanwood GD (2009) Prenatal exposure to
drugs: effects on brain development and implications for policy
and education. Nat Rev Neurosci 10:303–312
Tournier M, Sorbara F, Gindre C, Swendsen JD, Verdoux H (2003)
Cannabis use and anxiety in daily life: a naturalistic investigation
in a non-clinical population. Psychiatry Res 118:1–8
Trezza V, Vanderschuren LJ (2008a) Bidirectional cannabinoid
modulation of social behavior in adolescent rats. Psychopharma-
cology (Berl) 197:217–227
Trezza V, Vanderschuren LJ (2008b) Cannabinoid and opioid
modulation of social play behavior in adolescent rats: differential
behavioral mechanisms. Eur Neuropsychopharmacol 18:519–530
Trezza V, Campolongo P, Cassano T, Macheda T, Dipasquale P,
Carratu MR, Gaetani S, Cuomo V (2008a) Effects of perinatal
exposure to delta-9-tetrahydrocannabinol on the emotional
reactivity of the offspring: a longitudinal behavioral study in
Wistar rats. Psychopharmacology (Berl) 198:529–537
Trezza V, Cuomo V, Vanderschuren LJ (2008b) Cannabis and the
developing brain: insights from behavior. Eur J Pharmacol
585:441–452
Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998)
Immunohistochemical distribution of cannabinoid CB1 receptors
in the rat central nervous system. Neuroscience 83:393–411
Vardaris RM, Weisz DJ, Fazel A, Rawitch AB (1976) Chronic
administration of delta-9-tetrahydrocannabinol to pregnant rats:
studies of pup behavior and placental transfer. Pharmacol
Biochem Behav 4:249–254
Vela G, Martin S, Garcia-Gil L, Crespo JA, Ruiz-Gayo M, Javier
Fernandez-Ruiz J, Garcia-Lecumberri C, Pelaprat D, Fuentes JA,
Ramos JA, Ambrosio E (1998) Maternal exposure to delta9-
tetrahydrocannabinol facilitates morphine self-administration
behavior and changes regional binding to central mu opioid
receptors in adult offspring female rats. Brain Res 807:101–109
Viveros MP, Marco EM, File SE (2005) Endocannabinoid system and
stressandanxietyresponses.PharmacolBiochemBehav81:331–342
VorheesCV(1989)Conceptsinteratologyanddevelopmentaltoxicology
derived from animal research. Ann N YAcad Sci 562:31–41
Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H (2002)
Comparison of the subjective effects of Delta(9)-tetrahydrocan-
nabinol and marijuana in humans. Psychopharmacology (Berl)
161:331–339
Ward IL, Weisz J (1984) Differential effects of maternal stress on
circulating levels of corticosterone, progesterone, and testoster-
one in male and female rat fetuses and their mothers. Endocri-
nology 114:1635–1644
Weidenfeld J, Feldman S, Mechoulam R (1994) Effect of the brain
constituent anandamide, a cannabinoid receptor agonist, on the
hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinolo-
gy 59:110–112
Witkin JM, Tzavara ET, Nomikos GG (2005) A role for cannabinoid
CB1 receptors in mood and anxiety disorders. Behav Pharmacol
16:315–331
Psychopharmacology (2011) 214:5–15 15